Last reviewed · How we verify

Dose 1 of glycopyrronium, 2.5% QD — Competitive Intelligence Brief

Dose 1 of glycopyrronium, 2.5% QD (Dose 1 of glycopyrronium, 2.5% QD) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Anticholinergic. Area: Ophthalmology.

phase 2 Anticholinergic Muscarinic acetylcholine receptors Ophthalmology Small molecule Live · refreshed every 30 min

Target snapshot

Dose 1 of glycopyrronium, 2.5% QD (Dose 1 of glycopyrronium, 2.5% QD) — Journey Medical Corporation. Glycopyrronium is an anticholinergic that works by blocking the action of acetylcholine at muscarinic receptors, leading to reduced salivation and sweating.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
Dose 1 of glycopyrronium, 2.5% QD TARGET Dose 1 of glycopyrronium, 2.5% QD Journey Medical Corporation phase 2 Anticholinergic Muscarinic acetylcholine receptors
SCOPOLAMINE SCOPOLAMINE marketed Anticholinergic [EPC] Muscarinic acetylcholine receptors 1979-01-01
Enlon-Plus Atropine Sulfate Alcon Labs Inc marketed Antimuscarinic agent Muscarinic acetylcholine receptors 1960-01-01
Atropine sulfate and epinephrine Atropine sulfate and epinephrine Dar El Oyoun Hospital marketed Anticholinergic agent and sympathomimetic amine combination Muscarinic acetylcholine receptors (atropine); alpha-1, alpha-2, beta-1, and beta-2 adrenergic receptors (epinephrine)
Diclofenac oral + scopolamina oral Diclofenac oral + scopolamina oral Hospital de Clinicas de Porto Alegre marketed NSAID + anticholinergic combination COX-1/COX-2 (diclofenac); muscarinic acetylcholine receptors (scopolamine)
oxybutynin immediate release oxybutynin immediate release Astellas Pharma Inc marketed Anticholinergic Muscarinic acetylcholine receptors (M2 and M3)
Ipratropium/albuterol Ipratropium/albuterol National Jewish Health marketed Combination bronchodilator (anticholinergic + beta-2 agonist) Muscarinic acetylcholine receptors (ipratropium); beta-2 adrenergic receptor (albuterol)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Anticholinergic class)

  1. · 4 drugs in this class
  2. Pearl Therapeutics, Inc. · 3 drugs in this class
  3. Shionogi · 2 drugs in this class
  4. Ain Shams University · 1 drug in this class
  5. Astellas Pharma Inc · 1 drug in this class
  6. Boehringer Ingelheim · 1 drug in this class
  7. Covis · 1 drug in this class
  8. Forest Labs Inc · 1 drug in this class
  9. Fougera Pharms · 1 drug in this class
  10. Glaxo Grp England · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Dose 1 of glycopyrronium, 2.5% QD — Competitive Intelligence Brief. https://druglandscape.com/ci/dose-1-of-glycopyrronium-2-5-qd. Accessed 2026-05-17.

Build your own brief

Pick any drug + add comparators: